Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

The risk of adverse events depends on study design and disease. Studies on inflammatory bowel disease were often of short duration with frequent documentation of adverse events which resulted in higher adverse event rates whereas, in studies of rheumatoid arthritis, the longer follow-up may have resulted in lower adverse event rates. In most studies aimed at efficacy of glucocorticoids or other drugs, adverse events were not systematically assessed. Clear guidelines on assessment of adverse events are lacking.

 

 

Authors: Hoes, J. N.; Jacobs, J. W.; Verstappen, S. M.; Bijlsma, J. W.; Van der Heijden, G. J. 

Title: Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

Year: 2009

Journal: Ann Rheum Dis

Volume: 68

Issue: 12

Pages: 1833-8

Pubmed Link: Click here.

Previous Article

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy...

Next Article

Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis...